Grifols (GRFS) Income from Continuing Operations (2010 - 2020)
Grifols (GRFS) posted Income from Continuing Operations of 330091015.77 for Q1 2020, down 55.46% quarter-over-quarter from 741176413.24 in Q4 2019, and up 69.41% year-on-year from 194843192.77 in Q2 2019.
Grifols (GRFS) Income from Continuing Operations (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Income from Continuing Operations for 10 consecutive years, with 330091015.77 the latest figure, recorded in Q1 2020.
- Income from Continuing Operations for Q1 2020 came in at 330091015.77, up 69.41% year-over-year; the trailing twelve-month figure through Mar 2020 was 2068492905.63 (up 40.69% YoY), and the FY2025 annual result was 582021757.35, up 155.71% from the prior year.
- Income from Continuing Operations was 330091015.77 for Q1 2020 at Grifols, down from 741176413.24 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 882309060.91 in Q4 2017 and troughed at 101201471.58 in Q4 2016.
- Average Income from Continuing Operations over 5 years is 338766834.04, with a median of 247880765.26 recorded in 2017.
- Year-over-year, Income from Continuing Operations sank 154.07% in 2016 and soared 971.83% in 2017.
- Over 5 years, Income from Continuing Operations stood at 101201471.58 in 2016, then jumped by 971.83% to 882309060.91 in 2017, then decreased by 9.06% to 802382283.85 in 2018, then slipped by 7.63% to 741176413.24 in 2019, then sank by 55.46% to 330091015.77 in 2020.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 330091015.77 in Q1 2020, 741176413.24 in Q4 2019, and 194843192.77 in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 833.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 330.09 Mn |
| Dec 31, 2019 | 741.18 Mn |
| Mar 31, 2019 | 194.84 Mn |
| Dec 31, 2018 | 802.38 Mn |
| Sep 30, 2018 | 546.22 Mn |
| Jun 30, 2018 | 208.87 Mn |
| Mar 31, 2018 | 264.14 Mn |
| Dec 31, 2017 | 882.31 Mn |
| Jun 30, 2017 | 157.93 Mn |
| Mar 31, 2017 | 247.88 Mn |
| Dec 31, 2016 | -101.20 Mn |
| Sep 30, 2016 | 157.85 Mn |
| Jun 30, 2016 | 136.35 Mn |
| Mar 31, 2016 | 381.34 Mn |
| Dec 31, 2015 | 187.15 Mn |
| Sep 30, 2015 | 155.63 Mn |
| Jun 30, 2015 | -43.48 Mn |
| Mar 31, 2015 | 221.20 Mn |
| Dec 31, 2014 | -529.86 Mn |
| Sep 30, 2014 | 180.98 Mn |